抗hepcidin 治疗铁受限性贫血。
Anti-hepcidin therapy for iron-restricted anemias.
机构信息
UNIVERSITY OF CALIFORNIA, LOS ANGELES.
出版信息
Blood. 2013 Oct 24;122(17):2929-31. doi: 10.1182/blood-2013-08-522466.
Abstract
In this issue of Blood, Cooke et al demonstrate the potential of a fully human anti-hepcidin antibody as a novel therapeutic for iron-restricted anemias such as anemia of inflammation, cancer, or chronic kidney disease (formerly known as “anemia of chronic diseases”).
摘要
在本期《Blood》杂志中，Cooke 等人展示了一种全人源抗hepcidin 抗体作为一种新型治疗药物的潜力，用于治疗炎症、癌症或慢性肾脏病等铁受限性贫血（以前称为“慢性病贫血”）。
相似文献
1
Anti-hepcidin therapy for iron-restricted anemias.抗hepcidin 治疗铁受限性贫血。
Blood. 2013 Oct 24;122(17):2929-31. doi: 10.1182/blood-2013-08-522466.
2
A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates.一种全人源抗肝素肽抗体可调节小鼠和非人灵长类动物的铁代谢。
Blood. 2013 Oct 24;122(17):3054-61. doi: 10.1182/blood-2013-06-505792. Epub 2013 Aug 14.
3
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.一种铁调素降低剂可动员铁用于红细胞生成，在腺嘌呤诱导的大鼠贫血肾病模型中。
Nephrol Dial Transplant. 2013 Jul;28(7):1733-43. doi: 10.1093/ndt/gfs584. Epub 2013 Jan 22.
4
Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia.抗hepcidin 抗体治疗可调节铁代谢，在炎症性贫血的小鼠模型中有效。
Blood. 2010 Apr 29;115(17):3616-24. doi: 10.1182/blood-2009-09-245977. Epub 2010 Jan 6.
5
Hepcidin and iron disorders: new biology and clinical approaches.铁调素与铁代谢紊乱：新生物学与临床方法
Int J Lab Hematol. 2015 May;37 Suppl 1:92-8. doi: 10.1111/ijlh.12358.
6
Manipulation of the hepcidin pathway for therapeutic purposes.针对治疗目的对铁调素途径的操控。
Haematologica. 2013 Nov;98(11):1667-76. doi: 10.3324/haematol.2013.084624.
7
Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.炎症对慢性肾脏病患者铁蛋白、hepcidin 及缺铁性贫血管理的影响。
Nutrients. 2018 Aug 27;10(9):1173. doi: 10.3390/nu10091173.
8
Hepcidin: clinical utility as a diagnostic tool and therapeutic target.铁调素：作为诊断工具和治疗靶点的临床应用。
Kidney Int. 2011 Aug;80(3):240-4. doi: 10.1038/ki.2011.141. Epub 2011 Jun 15.
9
Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.接受血液透析的终末期肾病患者的血清铁调素水平
Saudi J Kidney Dis Transpl. 2015 Jan;26(1):19-25. doi: 10.4103/1319-2442.148716.
10
Hepcidin and Anemia: A Tight Relationship.铁调素与贫血：紧密关系
Front Physiol. 2019 Oct 9;10:1294. doi: 10.3389/fphys.2019.01294. eCollection 2019.
引用本文的文献
1
Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.慢性肾脏病和终末期肾病中铁缺乏性贫血的治疗
Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep.
2
Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.骨化三醇对慢性肾脏病患者血清铁调素的影响：一项随机对照试验。
BMC Nephrol. 2018 Feb 9;19(1):35. doi: 10.1186/s12882-018-0823-7.
3
Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.妇产科中耶和华见证人的管理：综合医学、伦理和法律方法
Obstet Gynecol Surv. 2016 Aug;71(8):488-500. doi: 10.1097/OGX.0000000000000343.
4
Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.铁平衡与铁调素在慢性肾脏病中的作用
Semin Nephrol. 2016 Mar;36(2):87-93. doi: 10.1016/j.semnephrol.2016.02.001.
5
[Hepcidin for iron homeostasis and target therapy in ironrelated disorders].用于铁稳态及铁相关疾病靶向治疗的铁调素
Zhonghua Xue Ye Xue Za Zhi. 2015 Nov;36(11):977-80. doi: 10.3760/cma.j.issn.0253-2727.2015.11.020.
6
Anemia in inflammatory bowel disease: an under-estimated problem?炎症性肠病中的贫血：一个被低估的问题？
Front Med (Lausanne). 2015 Jan 19;1:58. doi: 10.3389/fmed.2014.00058. eCollection 2014.
本文引用的文献
1
A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates.一种全人源抗肝素肽抗体可调节小鼠和非人灵长类动物的铁代谢。
Blood. 2013 Oct 24;122(17):3054-61. doi: 10.1182/blood-2013-06-505792. Epub 2013 Aug 14.
2
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).一项关于红细胞生成素、达贝泊汀和培非格司亭在癌症或慢性肾脏病患者中的安全性、疗效和应用的综述：来自南方不良反应网络（SONAR）的报告。
Semin Thromb Hemost. 2012 Nov;38(8):783-96. doi: 10.1055/s-0032-1328884. Epub 2012 Oct 30.
3
The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.亚铁血红素-铁蛋白系统作为贫血症和铁过载疾病的治疗靶点。
Hematology Am Soc Hematol Educ Program. 2011;2011:538-42. doi: 10.1182/asheducation-2011.1.538.
4
Hepcidin and disorders of iron metabolism.亚铁调素与铁代谢紊乱。
Annu Rev Med. 2011;62:347-60. doi: 10.1146/annurev-med-050109-142444.
5
Detection, evaluation, and management of iron-restricted erythropoiesis.铁缺乏性红细胞生成的检测、评估和管理。
Blood. 2010 Dec 2;116(23):4754-61. doi: 10.1182/blood-2010-05-286260. Epub 2010 Sep 8.
6
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).TMPRSS6基因的突变会导致铁难治性缺铁性贫血（IRIDA）。
Nat Genet. 2008 May;40(5):569-71. doi: 10.1038/ng.130. Epub 2008 Apr 13.
Zotero 插件